Understanding The Effect Of A Strong CYP3A4 Inducer On Glasdegib Pharmacokinetics

Phase 1 Completed 12 enrolled Pfizer

CrossoverOpen-labelBasic science

Summary

The study also aims to determine the effect of a strong enzyme (CYP3A4) inducer-rifampin- on drug exposure of Glasdegib. This study will be conducted in healthy subjects given a single dose of glasdegib in each period.

Timeline

Start: 2015-05
Primary completion: 2015-06
Completion: 2015-06

Publications

Shaik MN, Hee B, Wei H, LaBadie RR. Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteers. Br J Clin Pharmacol. 2018 Jun;84(6):1346-1353. doi: 10.1111/bcp.13568. Epub 2018 Apr 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Glasdegib	Small molecule	100 mg	Oral
Subject	Rifampin	Small molecule	600 mg	Oral

Indications

No indication recorded.